Canigen DHP Lyophilisate and Solvent for Suspension for Injection for Dogs

Safety and efficacy data are available which demonstrate that this vaccine can be mixed
and administered with the inactivated vaccines of the Canigen range against canine

Revised: November 2024
AN: 01815/2024
leptospirosis caused by all or some of the following serovars: L. interrogans serogroup
Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar
Copenhageni, serogroup Australis serovar Bratislava, and L. kirschneri
serogroup Grippotyphosa serovar Bananal/Liangguang.
After administration with one of the leptospirosis vaccines, a mild and transient increase in
body temperature (≤ 1 °C) may occur for a few days after vaccination, with some pups
showing less activity and/or a reduced appetite. A small transient swelling 4 cm), which
can occasionally be firm and painful on palpation, may be observed at the site of injection.
Any such swelling will either have disappeared or be clearly diminished by 14 days post-
vaccination.
After mixed administration of an overdose of Canigen DHP and an overdose of the
leptospirosis vaccines of the Canigen range, transient local reactions such as diffuse to
firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no
longer than 5 weeks, however some may take a little longer to completely disappear.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed
and administered with the inactivated vaccine of the Canigen range against rabies. After
administration with the rabies vaccine, where this product is authorised, transient local
reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed for
up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post dosing.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the same day, but not mixed, with the live vaccine for intranasal
administration of the Canigen range against infectious tracheobronchitis caused by
Bordetella bronchiseptica and/or canine parainfluenza virus.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered at the same time but not mixed with the inactivated vaccine of the Canigen
range against Bordetella bronchiseptica.
When Canigen DHP is used with any of the other Canigen vaccines referred to above, the
minimum vaccination age for each vaccine must be taken into account such that at the
time of vaccination, the dogs are at or older than the oldest minimum vaccination age for
the individual vaccines.
Consult product leaflets before administering products simultaneously.
No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal product except the products mentioned above. A decision to
use this vaccine before or after any other veterinary medicinal product therefore needs to
be made on a case by case basis.